Cefotetan

Cefotetan

250px
Systematic (IUPAC) name
(7S)-7-{[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene) 1,3-dithietane-2-carbonyl]amino}-7-methoxy- 3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
AHFS/Drugs.com	Consumer Drug Information
Pregnancy category	US: B (No risk in non-human studies)
Legal status	US: ℞-only
Routes of administration	Injection
Identifiers
CAS Number	69712-56-7 Y
ATC code	J01DC05 (WHO)
PubChem	CID: 53025
DrugBank	DB01330 N
ChemSpider	47904 Y
UNII	48SPP0PA9Q Y
KEGG	D00260 N
ChEBI	CHEBI:3499 N
ChEMBL	CHEMBL474579 N
Chemical data
Formula	C17H17N7O8S4
Molecular mass	575.623 g/mol
SMILES O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)C3S/C(S3)=C(/C(=O)N)C(=O)O)CSc4nnnn4C)C(=O)O
InChI InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/b12-6-/t13?,15-,17+/m1/s1 Y Key:SRZNHPXWXCNNDU-IXOPCIAXSA-N Y
NY (what is this?)  (verify)

Cefotetan is an injectable antibiotic of the cephamycin type for prophylaxis and treatment of bacterial infections. It is often grouped together with second-generation cephalosporins and has a similar antibacterial spectrum, but with additional anti-anaerobe coverage.

Cefotetan was developed by Yamanouchi. It is marketed outside Japan by AstraZeneca with the brand names Apatef and Cefotan.

Adverse effects

The chemical structure of cefotetan, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.

Spectrum of bacterial susceptibility

Cefotetan has a broad spectrum of activity and has been used to treat bacterial infections of the bone, skin, urinary tract, and lower respiratory tract. Notable species include Bacteroides, Streptococcus, and Escherichia. The following represents MIC susceptibility data for a few medically significant bacteria.

• Escherichia coli: 0.06 µg/mL
• Bacteroides fragilis: ≤0.06 µg/mL - 512 µg/mL
• Clostridium perfringins: 1 µg/mL - 4 µg/mL

External links

• Cefotan official web site run by AstraZeneca US
• Cefotetan entry in RxList